farletuzumab治疗卵巢癌将开始III期临床研究

2012-04-16 cyy123 cyy123

Eisai的分公司Morphotek，完成了FAR-131研究（III期）的志愿者招募工作，用于治疗第一次复发铂敏感卵巢癌患者。 III期farletuzumab研究将设置：随机、双盲、安慰剂控制等的对照。研究将评估两种不同剂量的farletuzumab结合标准治疗同只采用标准治疗的疗效，通过无进展存活率的改善来比较。初级终末点和次级终末点将研究：提高整体存活率，客观肿瘤应答及患者第二次

Eisai的分公司Morphotek，完成了FAR-131研究（III期）的志愿者招募工作，用于治疗第一次复发铂敏感卵巢癌患者。

III期farletuzumab研究将设置：随机、双盲、安慰剂控制等的对照。

研究将评估两种不同剂量的farletuzumab结合标准治疗同只采用标准治疗的疗效，通过无进展存活率的改善来比较。

初级终末点和次级终末点将研究：提高整体存活率，客观肿瘤应答及患者第二次缓解期长度。

farletuzumab是一种靶向定位叶酸受体α的人源化单克隆抗体，主要在非粘液上皮细胞卵巢癌内表达。（生物谷 bioon.com）

相关阅读：

NEJM：靶向疗法能延长无进展晚期卵巢癌患者寿命

Eisai中止开发Pariet/AcipHex（雷贝拉唑钠）胶囊

FDA批准审查了Eisai公司DACOGEN药物的补充新药申请

日本埃莎39亿美元收购美国MGI药业公司

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1649947, encodeId=c00d164994ef6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Sep 14 00:51:00 CST 2012, time=2012-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652680, encodeId=dc381652680ee, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Jun 25 08:51:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050136, encodeId=9d652050136aa, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 16 09:51:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911601, encodeId=ff6619116017e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 10 01:51:00 CST 2012, time=2012-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915751, encodeId=8b2d1915e5156, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 03 18:51:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524527, encodeId=0eb2152452e5c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594308, encodeId=879e15943089a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-09-14 huiwelcome

#II期临床研究#

32 0
[GetPortalCommentsPageByObjectIdResponse(id=1649947, encodeId=c00d164994ef6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Sep 14 00:51:00 CST 2012, time=2012-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652680, encodeId=dc381652680ee, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Jun 25 08:51:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050136, encodeId=9d652050136aa, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 16 09:51:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911601, encodeId=ff6619116017e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 10 01:51:00 CST 2012, time=2012-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915751, encodeId=8b2d1915e5156, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 03 18:51:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524527, encodeId=0eb2152452e5c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594308, encodeId=879e15943089a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-06-25 医生2402

#I期临床#

36 0
[GetPortalCommentsPageByObjectIdResponse(id=1649947, encodeId=c00d164994ef6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Sep 14 00:51:00 CST 2012, time=2012-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652680, encodeId=dc381652680ee, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Jun 25 08:51:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050136, encodeId=9d652050136aa, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 16 09:51:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911601, encodeId=ff6619116017e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 10 01:51:00 CST 2012, time=2012-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915751, encodeId=8b2d1915e5156, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 03 18:51:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524527, encodeId=0eb2152452e5c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594308, encodeId=879e15943089a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-08-16 tastas

#III期临床研究#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=1649947, encodeId=c00d164994ef6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Sep 14 00:51:00 CST 2012, time=2012-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652680, encodeId=dc381652680ee, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Jun 25 08:51:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050136, encodeId=9d652050136aa, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 16 09:51:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911601, encodeId=ff6619116017e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 10 01:51:00 CST 2012, time=2012-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915751, encodeId=8b2d1915e5156, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 03 18:51:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524527, encodeId=0eb2152452e5c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594308, encodeId=879e15943089a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-11-10 snf701207

#mAb#

25 0
[GetPortalCommentsPageByObjectIdResponse(id=1649947, encodeId=c00d164994ef6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Sep 14 00:51:00 CST 2012, time=2012-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652680, encodeId=dc381652680ee, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Jun 25 08:51:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050136, encodeId=9d652050136aa, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 16 09:51:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911601, encodeId=ff6619116017e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 10 01:51:00 CST 2012, time=2012-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915751, encodeId=8b2d1915e5156, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 03 18:51:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524527, encodeId=0eb2152452e5c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594308, encodeId=879e15943089a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-07-03 juliusluan78

#III#

39 0
[GetPortalCommentsPageByObjectIdResponse(id=1649947, encodeId=c00d164994ef6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Sep 14 00:51:00 CST 2012, time=2012-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652680, encodeId=dc381652680ee, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Jun 25 08:51:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050136, encodeId=9d652050136aa, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 16 09:51:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911601, encodeId=ff6619116017e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 10 01:51:00 CST 2012, time=2012-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915751, encodeId=8b2d1915e5156, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 03 18:51:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524527, encodeId=0eb2152452e5c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594308, encodeId=879e15943089a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-04-18 guihongzh

#II期临床#

34 0
[GetPortalCommentsPageByObjectIdResponse(id=1649947, encodeId=c00d164994ef6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Sep 14 00:51:00 CST 2012, time=2012-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652680, encodeId=dc381652680ee, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Jun 25 08:51:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050136, encodeId=9d652050136aa, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 16 09:51:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911601, encodeId=ff6619116017e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 10 01:51:00 CST 2012, time=2012-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915751, encodeId=8b2d1915e5156, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 03 18:51:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524527, encodeId=0eb2152452e5c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594308, encodeId=879e15943089a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-04-18 智智灵药

#III期#

28 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

药械

farletuzumab治疗卵巢癌将开始III期临床研究

相关资讯

科室

工具

服务